INTECH Investment Management’s Niagen Bioscience NAGE Stock Holding History

INTECH Investment Management’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$46.1K	Buy	14,463 +3,157	+28%	+$12.8K	﹤0.01%	2067
2026 Q1	$49.9K	Sell	11,306 -9,820	-46%	-$53K	﹤0.01%	2003
2025 Q4	$134K	Sell	21,126 -503	-2%	-$3.5K	﹤0.01%	2096
2025 Q3	$202K	Sell	21,629 -8,563	-28%	-$86.5K	﹤0.01%	2064
2025 Q2	$435K	Buy	30,192 +14,176	+89%	+$140K	﹤0.01%	1688
2025 Q1	$111K	Sell	16,016 -299	-2%	-$1.88K	﹤0.01%	2289
2024 Q4	$86.6K	Buy	+16,315	New	+$89.3K	﹤0.01%	2240

Other funds holding NAGE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

INTECH Investment Management's NAGE Position: Q2 2026 in Review

INTECH Investment Management increased its Niagen Bioscience (NAGE) stake by 28% in Q2 2026, buying an estimated $12.8K and bringing the position to 14,463 shares worth $46.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2067.

INTECH Investment Management first reported a position in NAGE in Q4 2024 and has held it in 7 quarters since. The position peaked at $435K in Q2 2025. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

INTECH Investment Management held 14,463 shares of Niagen Bioscience worth $46.1K as of Q2 2026.
INTECH Investment Management bought 3,157 Niagen Bioscience shares in Q2 2026, an estimated $12.8K.
Niagen Bioscience made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #2067 holding.
INTECH Investment Management first reported a position in Niagen Bioscience in Q4 2024 and has held it in 7 quarters since.
INTECH Investment Management's Niagen Bioscience position peaked at $435K in Q2 2025.
140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.